About: Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.48 (+1.37%)
LXRX NASDAQ Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals Inc share price
LXRX price activity
Last Price
$1.480
Change (24hr)
0.02 USD (1.37%)
Volume
1.95M
Volume (4w avg)
-
Open
$1.50
Day Range
$1.46 - $1.54
Previous Close
$1.46
Last Trade
04 Nov, 9:26 pm GMT+0
Delayed
04 Nov, 9:26 pm GMT+0
LXRX price performance
Delayed
04 Nov, 9:26 pm GMT+0
LXRX details
LXRX Market Signals